Bracco Imaging S.p.A. is a global diagnostic-imaging supplier whose products sit at the critical intersection of contrast media, scanner technology, and clinical interpretation. Public sources confirm a portfolio spanning CT, MRI, ultrasound, and nuclear medicine, with a legal base in Milan and a small internet routing footprint (AS211943). Evidence gaps include standalone financials, internal network use, and country-specific supply commitments. Key watchpoints are regulatory label changes, manufacturing continuity, and the commercial conversion of research alliances with NYU Langone Health and Subtle Medical.
Bracco Imaging operates in regulated diagnostic imaging, supplying contrast agents, microbubbles, radiopharmaceutical agents, injectors, software, and related services used by hospitals and radiology professionals. Its operating surface includes regulatory approvals across countries, a global R&D and manufacturing network, and strategic clinical-AI partnerships. A public internet registry footprint (AS211943) exists but is secondary to its medical-imaging role.
The company’s products sit at the convergence of imaging protocols, contrast enhancement, scanner workflow, and clinical interpretation. Changes in approvals, availability, safety labeling, manufacturing continuity, AI partnerships, or corporate network reachability can cascade to radiology departments, procurement decisions, and patient diagnostic confidence, making it a relevant entity for healthcare-infrastructure tracking.
The company’s products sit at the convergence of imaging protocols, contrast enhancement, scanner workflow, and clinical interpretation. Changes in approvals, availability, safety labeling, manufacturing continuity, AI partnerships, or corporate network reachability can cascade to radiology departments, procurement decisions, and patient diagnostic confidence, making it a relevant entity for healthcare-infrastructure tracking.
Bracco Imaging operates in regulated diagnostic imaging, supplying contrast agents, microbubbles, radiopharmaceutical agents, injectors, software, and related services used by hospitals and radiology professionals. Its operating surface includes regulatory approvals across countries, a global R&D and manufacturing network, and strategic clinical-AI partnerships. A public internet registry footprint (AS211943) exists but is secondary to its medical-imaging role.
Bracco Imaging impacts healthcare operations by supplying regulated imaging agents and technologies that influence scan quality and diagnostic workflow. A regulatory or supply disruption can delay exams, alter protocols, or increase costs; a new partnership or approval can shift clinical practice. The public internet registry signal is a secondary infrastructure indicator that may help assess corporate network changes but does not directly measure product availability.
Bracco Imaging S.p.A. is a global diagnostic-imaging supplier whose products sit at the critical intersection of contrast media, scanner technology, and clinical interpretation. Public sources confirm a portfolio spanning CT, MRI, ultrasound, and nuclear medicine, with a legal base in Milan and a small internet routing footprint (AS211943). Evidence gaps include standalone financials, internal network use, and country-specific supply commitments. Key watchpoints are regulatory label changes, manufacturing continuity, and the commercial conversion of research alliances with NYU Langone Health and Subtle Medical.
Bracco Imaging impacts healthcare operations by supplying regulated imaging agents and technologies that influence scan quality and diagnostic workflow. A regulatory or supply disruption can delay exams, alter protocols, or increase costs; a new partnership or approval can shift clinical practice. The public internet registry signal is a secondary infrastructure indicator that may help assess corporate network changes but does not directly measure product availability.
| 0.90–1.00 | A | High — direct sources |
| 0.75–0.89 | A/B | Strong |
| 0.55–0.74 | B/C | Medium |
| 0.35–0.54 | C/D | Weak–medium |
| 0.10–0.34 | D | Weak signal |
| 0.00–0.09 | D | Internal monitoring |
多个公开来源
Bracco Imaging S.p.A.
Bracco Imaging S.p.A. 是一家总部位于意大利米兰的诊断影像公司，致力于为全球医疗系统开发并提供造影剂、放射性药物、医疗器械及相关服务。拥有超过3,800名员工，业务遍及100多个国家，其产品在CT、MRI、超声和核医学工作流程中不可或缺。公司的公共互联网足迹（AS211943）是一个次要的企业基础设施信号，其次要于其受监管的医疗角色。
重要性
Bracco Imaging 通过供应受监管的影像剂和技术来影响医疗运营，这些技术影响扫描质量和诊断工作流程。监管或供应中断可能导致检查延误、方案更改或成本增加；而新的合作伙伴关系或批准可能改变临床实践。公共互联网注册信号是一个次要的基础设施指标，可能有助于评估企业网络变化，但并不能直接衡量产品的可用性。 另见: 谢尔盖·叶基莫夫.
公开来源显示
Bracco Imaging S.p.A. 是一家总部位于米兰的公司，为全球放射科部门提供造影剂、放射性药物及相关技术。其产品位于影像协议、对比增强和扫描解读的交汇点，使该公司成为诊断医学中的关键节点。其产品批准、供应连续性或研究方向的任何变化都可能波及医院工作流程和患者预后。 另见: TIM011 TIM011 CLOUD d.o.o..
官方公司页面描述了涵盖X射线/CT、MRI、超声、核医学和介入心脏病学的产品组合，拥有超过3,800名员工，支持100多个国家的医疗系统。一份意大利政府出版物确认了其在米兰via E. Folli 50的合法身份。公共互联网路由记录将该公司与自治系统AS211943及一条已宣告的IPv4路由相关联，暗示了较小的企业网络足迹。 另见: AKNET 互联网与信息系统有限公司.
公司的运营面包括受监管的药品、医疗器械、注射器和成像软件，这些都与每个市场的监管批准挂钩。位于意大利、瑞士、美国和中国的研发基地表明了持续的创新努力，约10%的参考营业额被投入到研发中。 另见: Azarakhsh Ava-e Ahvaz Co.
战略合作伙伴关系——最近与NYU Langone Health的多年联盟以及与Subtle Medical的AI驱动MRI协议——显示了对先进图像分析和临床AI的刻意推进。 另见: Windhoos.
物质控制面是已获批准的造影剂和放射性药物组合。制造连续性、药物警戒义务以及国家特定的标签决定了产品在何处以及如何使用。公司的互联网注册存在（AS211943）是企业基础设施的次要指标，而非产品可用性的衡量标准。 另见: EuroNet.
读者应关注监管公告中的标签变更、新适应症或安全通报。生产基地或批次放行中断可能影响影像能力。研究联盟转化为商业化部署产品将标志着竞争格局的变化。 另见: DU jiarui.
本次评估中未验证Bracco Imaging S.p.A.的独立审计年度报告，因此财务规模声明依赖于官方公司简介。路由证据仅限于ASN注册和单条路由；它并未揭示内部网络使用情况。产品可用性因司法管辖区而异，公开来源无法揭示私人供应合同。
本概况引用了Bracco.com官方页面、RIPE RDAP记录、镜像Whois服务以及意大利官方公报中的一则通知。所有来源均为截至2026年中期的低风险官方出版物。
运营面
Bracco Imaging 在受监管的诊断影像领域运营，供应造影剂、微泡、放射性药物、注射器、软件以及医院和放射科专业人员使用的相关服务。其运营面包括各国监管批准、全球研发和制造网络以及战略临床AI合作伙伴关系。存在公共互联网注册足迹（AS211943），但其次要于其医学影像角色。
公司的产品位于影像协议、对比增强、扫描仪工作流程和临床解读的汇合点。批准、可用性、安全标签、制造连续性、AI合作伙伴关系或企业网络可达性的任何变化都可能波及放射科、采购决策和患者诊断信心，使其成为医疗基础设施跟踪的相关实体。
监测点
Bracco Imaging的战略价值在于其双重角色：既是关键造影剂的医疗提供商，又是AI赋能影像研究的活跃合作伙伴。监管监督、制造复杂性和临床整合的汇聚创造了一个广泛的影响面。互联网路由存在是企业基础设施的滞后指标，而非主要运营信号。
按司法管辖区跟踪新的监管批准、标签变更和安全警报；监测生产基地公告以确保供应连续性；关注与NYU Langone和Subtle Medical的AI研究协议的商业部署；并注意AS211943下路由的任何扩展或撤销。
Bracco Imaging S.p.A.的独立审计财务数据未经验证；当前评估依赖于官方公司指标。内部网络使用和流量不透明。在做出市场特定声明之前，需要验证当地监管来源以确认特定国家的产品可用性。
来源
- Registry RDAP / WHOIS 记录- 公开来源身份和Bracco Imaging S.p.A.的注册背景。
- bracco.com- 标识Bracco Imaging为全球诊断影像公司，拥有造影剂、CEUS微泡、分子影像/PET试剂、专业医疗设备及相关服务的产品组合，并指出拥有超过3,800名员工，支持100多个国家的医疗系统。
- bracco.com- 描述了Bracco集团的业务领域以及Bracco Imaging在造影剂、X射线/CT、MRI、CEUS、分子影像、设备和服务方面的诊断影像产品组合。
- bracco.com- 展示了Bracco在X射线/CT、MRI、超声、核医学和介入心脏病学方面的诊断影像模态覆盖，并指出市场可用性因市场而异。
- bracco.com- 指出Bracco集团将约10%的参考营业额投资于研发，并描述了研究中心、影像剂开发、可持续流程和AI相关工作。
- bracco.com- 描述了Bracco的研究和运营设施，包括日内瓦和伊夫雷亚站点，以及英国、瑞士、德国、美国和中国的额外研究设施。
- gazzettaufficiale.it- 意大利官方出版物确认BRACCO IMAGING S.P.A.，注册地址为米兰via E. Folli 50，税号07785990156，并且Bracco Imaging SpA是药品授权变更通知的持有人。
- Registry RDAP / WHOIS 记录- 镜像RIPE whois和AS211943/BRACCO-AS的路由详细信息，包括组织名称Bracco Imaging S.p.A.、ORG-BIS28-RIPE、LIR类型、上游导入/导出以及可见的IPv4路由185.85.252.0/24。
- bracco.com- 宣布2026年4月20日Bracco Imaging与NYU Langone Health通过一项多年主研究协议建立战略联盟，专注于MRI、光子计数CT、靶向超声以及AI支持的PET/CT和MRI图像分析。
- bracco.com- 宣布2023年9月21日Bracco Imaging S.p.A.与Subtle Medical就增强对比MRI中的AI驱动图像采集达成全球协议。
- bracco.com- 描述了Blue Earth Diagnostics作为Bracco集团的一部分，在2019年被Bracco Imaging收购后，并解释了其分子影像和PET放射性药物的角色。
Domain of operation
Bracco Imaging S.p.A. is a diagnostic-imaging company based in Milan, Italy, that develops and supplies contrast agents, radiopharmaceuticals, medical devices, and related services to healthcare systems globally. With over 3,800 employees and a presence in more than 100 countries, its products are integral to CT, MRI, ultrasound, and nuclear medicine workflows. The company’s public internet footprint (AS211943) is a minor corporate infrastructure signal, secondary to its regulated medical role.
- Registry RDAP / WHOIS record: public-source identity and registry context for Bracco Imaging S.p.A.. 证据基础: source-4c673b12b3c0
时间线
- Bracco Imaging S.p.A. public evidence observed
The company’s products sit at the convergence of imaging protocols, contrast enhancement, scanner workflow, and clinical interpretation. Changes in approvals, availability, safety labeling, manufacturing continuity, AI partnerships, or corporate network reachability can cascade to radiology departments, procurement decisions, and patient diagnostic confidence, making it a relevant entity for healthcare-infrastructure tracking.
概要
- 名称: Bracco Imaging S.p.A.
- 类型: Digital infrastructure institution
- 所在地: Global
- 档案重点: Institution
功能说明
- public operating records
- official service pages
- documented relationships updates
重要性
- Bracco Imaging impacts healthcare operations by supplying regulated imaging agents and technologies that influence scan quality and diagnostic workflow. A regulatory or supply disruption can delay exams, alter protocols, or increase costs; a new partnership or approval can shift clinical practice. The public internet registry signal is a secondary infrastructure indicator that may help assess corporate network changes but does not directly measure product availability.
- 运营关键性: Medium
- 时间范围: Next quarter
关注事项
- official company sources
- public registries
- operator-published records
跟踪经验证的来源更新、角色变化和当前公开证据。
Bracco Imaging impacts healthcare operations by supplying regulated imaging agents and technologies that influence scan quality and diagnostic workflow. A regulatory or supply disruption can delay exams, alter protocols, or increase costs; a new partnership or approval can shift clinical practice. The public internet registry signal is a secondary infrastructure indicator that may help assess corporate network changes but does not directly measure product availability.
长期相关性取决于经验证的运营、政策和关系变化。
会员简报
深度档案背景
登录后可解锁完整档案简报和来源说明。
公开视角
Bracco Imaging impacts healthcare operations by supplying regulated imaging agents and technologies that influence scan quality and diagnostic workflow. A regulatory or supply disruption can delay exams, alter protocols, or increase costs; a new partnership or approval can shift clinical practice. The public internet registry signal is a secondary infrastructure indicator that may help assess corporate network changes but does not directly measure product availability.
观察点
- Bracco Imaging’s strategic value lies in its dual role: a healthcare provider of critical contrast agents and an active partner in AI-enabled imaging research.
- The convergence of regulatory oversight, manufacturing complexity, and clinical integration creates a wide impact surface.
- The internet routing presence is a lagging indicator of corporate infrastructure, not a primary operational signal.
限制说明
- Public evidence is used only for source-backed claims.
- Private control or contract claims require separate public support.
常见问题
Why does BTW track Bracco Imaging S.p.A.?
The company’s products sit at the convergence of imaging protocols, contrast enhancement, scanner workflow, and clinical interpretation. Changes in approvals, availability, safety labeling, manufacturing continuity, AI partnerships, or corporate network reachability can cascade to radiology departments, procurement decisions, and patient diagnostic confidence, making it a relevant entity for healthcare-infrastructure tracking.
What evidence supports the profile?
public-source identity and registry context for Bracco Imaging S.p.A..
What should readers watch next?
Bracco Imaging’s strategic value lies in its dual role: a healthcare provider of critical contrast agents and an active partner in AI-enabled imaging research.
